Head to Head Contrast: TG Therapeutics (NASDAQ:TGTX) vs. Kymera Therapeutics (NASDAQ:KYMR)

Kymera Therapeutics (NASDAQ:KYMR) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Earnings and Valuation

This table compares Kymera Therapeutics and TG Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21 million	234.88	-$311.35 million	($3.24)	-34.19
TG Therapeutics	$616.29 million	13.45	$447.18 million	$2.74	19.77

TG Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kymera Therapeutics and TG Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-21.22%	-19.21%
TG Therapeutics	55.22%	73.49%	34.14%

Volatility & Risk

Kymera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Kymera Therapeutics and TG Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1	2	23	1	2.89
TG Therapeutics	1	2	6	0	2.56

Kymera Therapeutics presently has a consensus target price of $134.68, indicating a potential upside of 21.60%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 16.30%. Given Kymera Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than TG Therapeutics.

Insider and Institutional Ownership

58.6% of TG Therapeutics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

TG Therapeutics beats Kymera Therapeutics on 8 of the 15 factors compared between the two stocks.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.